Gilead Sciences, Inc.

NASDAQ:GILD  
68.50
+0.69 (+1.02%)
4:19:35 PM EDT: $68.47 -0.03 (-0.04%)
Products, Strategic Combinations, Regulatory

Gilead Announces Clinical Trial Collaborations With Merck

Published: 01/10/2022 13:54 GMT
Gilead Sciences, Inc. (GILD) - Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With Keytruda® in First-line Metastatic Non-small Cell Lung Cancer.
Gilead Sciences Inc - Gilead Will Sponsor a Phase 2 Signal-seeking Study Evaluating Combinations That Include Pembrolizumab in First-line Nsclc.
Gilead-merck to Sponsor Global Phase 3 Clinical Trial of Trodelvy in Combination With Keytruda As First-line Treatment for Patients With Metastatic Nsclc.
Gilead Sciences - Everest Medicines Will Also Participate in Global Phase 3 Study in Asia Through Its Existing Collaboration Agreement With Gilead.